Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals is a developmental stage pharmaceutical company based in Jericho, New York. It develops botanical drugs for patients with immune and inflammatory diseases. Its lead drug candidate, Phyto-N, is a botanical extract derived from a medicinal plant used in traditional Chinese medicine. Curanex’s drug development pipeline covers ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease and gout. Its research for these indications is limited to preclinical studies, and Phyto-N has not received regulatory approval as a drug in any jurisdiction. The company also researches the active chemical compounds in Phyto-N. In February 2026, Curanex completed a pilot-scale batch manufactured under Good Manufacturing Practice standards.
No SEC Form 4 filings for $CURX in the last 30 days.
See all $CURX insider activity →Curanex Pharmaceuticals (CURX) reported a nine-month net loss of $9.26M, with cash declining to $977K by September 30, 2026. The company raised $13.2M in its 2025 IPO and awaits FDA feedback on its IND submission by December 11, 2026. Curanex has no revenue and faces cash burn concerns.
Curanex Pharmaceuticals Inc (CURX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Legal Proceedings On July 23, 2026, Daymond Morales, et al., filed a putative securities class action in the Supreme Court of the State of New York, New York County (Index No. 159271/2026), against the Company and its underwriters Dominari Securities LLC,
Curanex Pharmaceuticals Inc. (CURX) completed its IPO in 2025, raising $17.25 million, but reported no revenue and a net loss of $4.2 million due to increased R&D and general & administrative expenses. Its flagship product, Phyto-N, is in preclinical development, with an IND submission for ulcerative colitis planned for late 2026. The company faces ongoing material weaknesses in internal controls and risks related to its Nasdaq listing.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CURX (Curanex Pharmaceuticals Inc). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent CURX coverage spans financial news and earnings.
Negative earnings surprise and low cash balance likely pressure the stock lower.
The lawsuits introduce litigation risk and potential share price pressure.
Curanex Pharmaceuticals (CURX) has completed its IPO, raising $17.25 million, but faces challenges including no current revenue, a net loss of $4.2 million, internal control weaknesses, and risks associated with its Nasdaq listing. The company's focus on R&D for Phyto-N, which is still in preclinical stages, suggests limited immediate commercial potential.
The appointment of two experienced advisors to Curanex's scientific board signals strategic focus on advancing its lead botanical drug candidate, Phyto-N, toward IND submission and Phase I trials. This development could positively influence investor sentiment and stock performance, especially as the company approaches key clinical milestones.
Curanex Pharmaceuticals' successful GMP pilot batch and upcoming IND submission suggest potential positive catalyst for stock.
AlphAI scores every news story that mentions CURX with an AI model for sentiment and relevance, and aggregates insider trades from Curanex Pharmaceuticals Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Curanex Pharmaceuticals (CURX) reported a nine-month net loss of $9.26M, with cash declining to $977K by September 30, 2026. The company raised $13.2M in its 2025 IPO and awaits FDA feedback on its IND submission by December 11, 2026. Curanex has no revenue and faces cash burn concerns.
Curanex Pharmaceuticals Inc (CURX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Legal Proceedings On July 23, 2026, Daymond Morales, et al., filed a putative securities class action in the Supreme Court of the State of New York, New York County (Index No. 159271/2026), against the Company and its underwriters Dominari Securities LLC,
Curanex Pharmaceuticals Inc. (CURX) completed its IPO in 2025, raising $17.25 million, but reported no revenue and a net loss of $4.2 million due to increased R&D and general & administrative expenses. Its flagship product, Phyto-N, is in preclinical development, with an IND submission for ulcerative colitis planned for late 2026. The company faces ongoing material weaknesses in internal controls and risks related to its Nasdaq listing.
Curanex Pharmaceuticals Inc. has appointed Dr. Taku Kambayashi and Dr. Selvakumar Subbian to its Scientific Advisory Board, enhancing its expertise as it prepares for an Investigational New Drug (IND) filing for its lead candidate, Phyto-N. The company, which focuses on botanical drugs for inflammatory diseases, aims for IND submission and Phase I clinical trials in Q4 2026. Despite recent stock declines, Curanex (NASDAQ:CURX) shows financial stability with strong liquidity and more cash than debt.
Curanex Pharmaceuticals Inc. announced the successful completion of a GMP-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N. This milestone is crucial for its planned Investigational New Drug (IND) submission for ulcerative colitis, targeted for Q4 2026. The company is now advancing GLP toxicology and pharmacokinetic studies to support the regulatory submission.
Curanex (Nasdaq: CURX) has completed a GMP-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N, as it prepares for an Investigational New Drug (IND) submission for ulcerative colitis. The company is targeting a Q4 2026 IND submission and is advancing GLP toxicology and pharmacokinetic studies. This milestone follows positive non-GLP safety studies and positions Curanex for future clinical development.
Jericho, New York, Sept. 12, 2025 ( GLOBE NEWSWIRE ) -- Curanex Pharmaceuticals Inc. ( Nasdaq: CURX ) ( "Curanex" or the "Company" ) , a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced that Dominari ...
